Zepteon

Zepteon is a platform technology company focused on revolutionizing antibody manufacturing through its patented Glycap-3A affinity chromatography resin. This technology selectively purifies antibodies with nonfucosylated or bisected glycoforms, which are associated with increased antibody-dependent cellular cytotoxicity (ADCC) and enhanced therapeutic efficacy against cancer, infectious diseases, and autoimmune disorders. Founded in 2012 as a spin-out from a large pharmaceutical company, Zepteon has established a customer base and secured key patents. The company is led by a seasoned team with deep expertise in bioprocessing and drug development, positioning it to capitalize on the growing demand for more effective and efficiently produced biologics.

Glycap-3A affinity chromatography resin that separates antibodies and Fc-fusion proteins based on specific glycoforms (nonfucosylated or bisected GlcNAc) to enrich for variants with enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC).

Zepteon competes with broad chromatography resin suppliers (e.g., Cytiva, Thermo Fisher) and alternative methods for controlling glycosylation, such as cell line engineering and culture media optimization. Its unique value proposition is its specific, preparative-scale separation of glycoforms based on a biological mechanism (FcγRIIIa binding), which is protected by key patents.